UK markets close in 4 hours 2 minutes

GenSight Biologics S.A. (GSGTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.75000.0000 (0.00%)
At close: 10:32AM EDT

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Bernard Gilly Ph.D.Co-Founder, CEO & Exec. Director640.46kN/A1957
Ms. Marie-Claude HoltzDeputy CEO, Quality VP & Chief Pharmacist128.92kN/AN/A
Dr. Jose-Alain Sahel M.D., Ph.D.Scientific Founder, Vice Chairman of Scientific Advisory Board & Board ObserverN/AN/AN/A
Prof. Botond RoskaScientific Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Jean E. Bennett M.D., Ph.D.Scientific Founder & Vice Chairman of Scientific Advisory BoardN/AN/A1955
Dr. Luk H. Vandenberghe M.D., Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Serge PicaudScientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Prof. Constance L. CepkoScientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Thomas GidoinChief Financial OfficerN/AN/A1983
Mr. Scott JeffersChief Technical OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Corporate governance

GenSight Biologics S.A.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.